HB1418 (2018) Detail

(New Title) relative establishing a commission to study greater transparency in pharmaceutical costs and drug rebate programs.


CHAPTER 350

HB 1418-FN - FINAL VERSION

 

6Mar2018... 0782h

04/26/2018   1599s

23May2018... 2107-EBA

2018 SESSION

18-2010

01/10

 

HOUSE BILL 1418-FN

 

AN ACT relative to establishing a commission to study greater transparency in pharmaceutical costs and drug rebate programs.

 

SPONSORS: Rep. Butler, Carr. 7; Rep. Rosenwald, Hills. 30; Rep. Kurk, Hills. 2

 

COMMITTEE: Commerce and Consumer Affairs

 

-----------------------------------------------------------------

 

AMENDED ANALYSIS

 

This bill establishes a commission to study greater transparency in pharmaceutical costs and drug rebate programs.

 

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

 

Explanation: Matter added to current law appears in bold italics.

Matter removed from current law appears [in brackets and struckthrough.]

Matter which is either (a) all new or (b) repealed and reenacted appears in regular type.

6Mar2018... 0782h

04/26/2018   1599s

23May2018... 2107-EBA 18-2010

01/10

 

STATE OF NEW HAMPSHIRE

 

In the Year of Our Lord Two Thousand Eighteen

 

AN ACT relative to establishing a commission to study greater transparency in pharmaceutical costs and drug rebate programs.

 

Be it Enacted by the Senate and House of Representatives in General Court convened:

 

350:1  New Subdivision; Commission to Study Greater Transparency in Pharmaceutical Costs and Drug Rebate Programs.  Amend RSA 126-A by inserting after section 75 the following new subdivision:

Commission to Study Greater Transparency in Pharmaceutical Costs and Drug Rebate Programs

126-A:76  Commission to Study Greater Transparency in Pharmaceutical Costs and Drug Rebate Programs Established.

I.  There is established a commission to study greater transparency in pharmaceutical costs and drug rebate programs.

(a)  The members of the commission shall be as follows:

(1)  Three members of the house of representatives, appointed by the speaker of the house of representatives.

(2)  One member of the senate, appointed by the president of the senate.

(3)  The insurance commissioner, or designee.

(4)  The commissioner of the department of health and human services, or designee.

(5)  One public member, appointed by the governor.

(6)  A representative of the New Hampshire Hospital Association, appointed by the association.

(7)  A physician licensed under RSA 329, appointed by the New Hampshire Medical Society.

(8)  The executive director of New Futures, or designee.

(9)  A representative of the New Hampshire Pharmacists Association, appointed by the association.

(10)  A representative of the Business and Industry Association of New Hampshire, appointed by the association.

(11) A member representing pharmacy benefit managers, appointed by the Pharmaceutical Care Management Association.

(12)  A representative of America's Health Insurance Plans (AHIP), appointed by that organization.

(13)  A representative of Pharmaceutical Research and Manufacturers of America, appointed by that organization.

(b)  Legislative members of the commission shall receive mileage at the legislative rate when attending to the duties of the commission.

II.(a)(1)  The commission shall study how to achieve greater transparency in pharmaceutical costs by identifying and analyzing certain critical prescription drugs and their role in overall health care spending in the New Hampshire and by analyzing the amounts rebated by drug manufacturers for certain high cost and high utilization prescription drugs.  The commission's study shall include, but not be limited to:

(A)  Studying strategies available to achieve greater transparency in pharmaceutical costs by identifying and analyzing certain critical prescription drugs and their role in overall health care spending and the impact of price increases on patients and their families.

(B)  Reviewing legislative efforts in other states and taking advantage of any other analysis by outside organizations or foundations.

(C)  Analyzing the impact of drug prices on insurance premium costs, consumer out-of-pocket costs for prescription drugs, and state and county purchasing of prescription drugs.

(D)  Analyzing the potential impact of transparency in relation to the practices of pharmaceutical manufacturers and pharmacy benefits managers, including how research and development, marketing, and rebates affect drug prices.

(E)  Proposing changes to New Hampshire law, as needed, to reduce the rising cost of pharmaceuticals.

(2)  The commission shall also study the role pharmacy benefit managers  play in the cost, administration, and distribution of prescription drugs; if greater transparency in pharmaceutical costs to purchasers would lower costs in overall health care spending in New Hampshire; and analyzing the amounts rebated by drug manufacturers for prescription drugs passed to purchasers and patients.  The goal shall be to determine if any changes to New Hampshire laws could reduce the rising cost of pharmaceuticals to purchasers or patients.

(b)  The commission may solicit input from any person or entity the commission deems relevant to its study.

III.  The members of the commission shall elect a chairperson from among the members.  The first meeting of the commission shall be called by the first-named house member.  The first meeting of the commission shall be held within 45 days of the effective date of this section.  Eight members of the commission shall constitute a quorum.

IV.  The commission shall make a report with its findings and any recommendations for proposed legislation on or before November 1, 2018 to the speaker of the house of representatives, the president of the senate, the house clerk, the senate clerk, the governor, and the state library.

350:2  Repeal.  RSA 126-A:76, relative to a commission to study greater transparency in pharmaceutical costs and drug rebate programs, is repealed.

350:3  Contingent Renumbering.  If HB 1356 of the 2018 regular legislative session becomes law then RSA 126-A:75 as inserted by section 1 of this act, and as repealed by section 2 of this act, shall be renumbered as RSA 126-A:77.

350:4  Effective Date.  

I.  Section 2 of this act shall take effect November 1, 2018.

II.  The remainder of this act shall take effect upon its passage.

 

Approved: July 02, 2018

Effective Date:

I. Section 2 shall take effect November 1, 2018.

II. Remainder shall take effect July 2, 2018.

 

 

Links

HB1418 at GenCourtMobile

Action Dates

Date Body Type
Jan. 17, 2018 House Hearing
Feb. 21, 2018 House Exec Session
House Floor Vote
March 6, 2018 House Floor Vote
March 20, 2018 Senate Hearing
April 26, 2018 Senate Floor Vote

Bill Text Revisions

HB1418 Revision: 4281 Date: July 3, 2018, 3:58 p.m.
HB1418 Revision: 3829 Date: June 6, 2018, 12:40 p.m.
HB1418 Revision: 3624 Date: May 25, 2018, 10:10 a.m.
HB1418 Revision: 3213 Date: March 13, 2018, 11:38 a.m.
HB1418 Revision: 2155 Date: Nov. 3, 2017, 12:17 p.m.

Docket

Date Status
Jan. 3, 2018 Introduced 01/03/2018 and referred to Commerce and Consumer Affairs HJ 1 P. 10
Jan. 17, 2018 Public Hearing: 01/17/2018 01:15 PM LOB 302
Jan. 30, 2018 Subcommittee Work Session: 01/30/2018 11:15 AM LOB 302
Jan. 30, 2018 Subcommittee Work Session: 01/30/2018 01:15 PM LOB 302
Feb. 20, 2018 Subcommittee Work Session: 02/20/2018 09:30 AM LOB 302
Feb. 21, 2018 Subcommittee Work Session: 02/21/2018 09:30 AM LOB 302
Feb. 21, 2018 Executive Session: 02/21/2018 LOB 302
Committee Report: Ought to Pass with Amendment # 2018-0782h (NT) (Vote 18-1; RC)
March 6, 2018 Committee Report: Ought to Pass with Amendment # 2018-0782h (NT) for 03/06/2018 (Vote 18-1; RC) HC 9 P. 37
March 6, 2018 Amendment # 2018-0782h: AA VV 03/06/2018 HJ 6 P. 66
March 6, 2018 Ought to Pass with Amendment 0782h: MA RC 312-17 03/06/2018 HJ 6 P. 66
March 8, 2018 Introduced 03/08/2018 and Referred to Health and Human Services; SJ 7
March 20, 2018 Hearing: 03/20/2018, Room 101, LOB, 01:15 pm; SC 13
April 26, 2018 Committee Report: Ought to Pass with Amendment # 2018-1599s, 04/26/2018; SC 18
April 26, 2018 Committee Amendment # 2018-1599s, AA, VV; 04/26/2018; SJ 14
April 26, 2018 Ought to Pass with Amendment 2018-1599s, MA, VV; OT3rdg; 04/26/2018; SJ 14
May 10, 2018 House Concurs with Senate Amendment 1599s (Rep. Hunt): MA VV 05/10/2018
May 23, 2018 Enrolled Bill Amendment # 2018-2107e Adopted, VV, (In recess of 05/23/2018); SJ 18
May 23, 2018 Enrolled Bill Amendment # 2018-2107e: AA VV 05/23/2018
May 23, 2018 Enrolled (In recess 05/23/2018); SJ 18
May 23, 2018 Enrolled 05/23/2018
Signed by Governor Sununu 07/02/2018; Chapter 350; I. Sec 2 eff 11/01/2018;II. Rem eff 07/02/2018